On May 16, 2012, a Report setting out the follow-up
recommendations of the DIP Working Group (DIP-WG) on the pilot
implementation of the DIP Methodology was released by the PMPRB. In
its report, the DIP-WG recommended that the Board adopt the DIP
Methodology on a permanent basis.
The DIP Methodology was introduced to address situations where
the price of a patented medicine increases in excess of that
allowable under the CPI-Adjustment Methodology due to a reduction
or termination of benefits to customers (i.e., any reduction given
as a promotion or in the form of rebates, discounts, refunds, free
goods, free services, gifts or any other benefits of a like
nature). Under the DIP Methodology, when a Market-Specific Average
Transaction Price of a drug product increases by more than that
allowable under the CPI-Adjustment Methodology and the patentee
provides the required evidence, the price of the drug product may
increase up to the highest Non-Excessive Average Price of another
class of customer without being presumed to be excessive, as long
as this price does not exceed the Highest International Price
The DIP-WG was established to identify potential challenges, and
develop workable solutions, in implementing the DIP Methodology.
The challenges identified mainly involved the seemingly onerous
evidence requirements to invoke the DIP Methodology. In order to
simplify the evidence reporting task, the DIP-WG proposed that the
DIP Methodology be divided into two streams: (i) a Simplified DIP
Methodology with lower evidence requirements, for situations where
the National Average Transaction Price (N-ATP) of a patented drug
product does not exceed its Introductory Benchmark Price (IBP); and
(ii) a Regular DIP Methodology with greater evidence requirements,
to be considered in situations when the N-ATP of a patented drug
product is greater than its IBP. The Board chose to implement the
DIP-WG's recommendations on a one-year pilot basis.
Based on its assessment of the pilot implementation, the DIP-WG
concluded that the DIP Methodology is an effective solution to
address and resolve investigations arising from the reduction or
termination of benefits. Moreover, the DIP-WG reported that the
pilot application was generally a positive experience for both
patentees and Board Staff due to the less burdensome process to
request and invoke the DIP Methodology, standardized means to
report required evidence, and manageable and operationally
available evidence requirements.
Effective September 1, 2016, the Disposition of Surplus Real Property Regulation to the Ontario Education Act was amended with the intention to reduce barriers to the formation of health and community hubs in Ontario.
This appeal relates to two generic drug submissions for two different products: exemestane and infliximab. Both submissions cross-referenced the submission of another generic company that had received a Notice of Compliance.
Two recent decisions from the Supreme Court of Canada directly affect Quebec's farm businesses by confirming La Financière Agricole du Québec's discretion in the administration of the farm income stabilization program...
On October 6, 2016, the Ontario Legislature reintroduced the Patients First Act, 2016 as Bill 41. Bill 41 is very similar to its predecessor, Bill 210, which was introduced in June 2016, but makes some important changes to the previous bill.
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).